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A 58-year-old woman with stage 4 adenocarcinoma of the lung being treated with pembrolizumab
developed dyspnea, non-productive cough, and a right middle lobe inﬁltrate. Complete resolution of the
inﬁltrate with cessation of pembrolizumab, initiation of prednisone and no antibiotic therapy suggested
drug-associated lung toxicity as the cause. While the programmed death-1 (PD-1) inhibitors
epembrolizumab and nivolumab e have been implicated as a cause of diffuse or multifocal pulmonary
inﬁltrates, the current case represents, to our knowledge, the ﬁrst instance of a unilobar, focal inﬁltrate
associated with their use. We speculate that the blockade of immune tolerance that is the hallmark of
PD-1 inhibitors might cause atypical inﬂammatory reactions such as the focal lobar inﬁltrate seen in the
current patient. Awareness of this novel radiographic pattern of drug-associated lung toxicity may
enhance clinicians' management of patients receiving.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The programmed death-1 (PD-1) pathway is a critical mecha-
nism of immune evasion used by lung tumors to co-opt the host
immune response. PD-1 is a co-inhibitory receptor expressed
mainly on T-cells and, to a lesser extent, on other immune cells. The
degree of PD-1 expression and engagement with its ligands de-
termines the fate of T-cells. Complex orchestration of co-activation
signals and co-inhibitory signals is critical to prevent auto-
immunity. PD-1 has two known ligands, PD-L1 and PD-L2. PD-1
interactions with PD-L1/PD-L2 in the normal lung are tightly
regulated to prevent inadequate or excessive inﬂammation [1e3].
Two new drugs that target the PD-1 pathway - nivolumab and
pembrolizumab, also called checkpoint inhibitors - have shown
promising clinical activity in lung cancer, melanoma, and renal cell
cancer [4]. Several reports have described pulmonary toxicity with
these drugs [5,6,11,12]. The reported radiographic patterns in these
cases have been either multifocal or diffuse. To our knowledge,
radiologically focal lung toxicity attributable to checkpoint, Cleveland Clinic, Cleveland,
Ltd. This is an open access article uinhibitors has not been reported. Based on our recent experience
with a patient who developed a rightmiddle lobe inﬁltrate ascribed
to pembrolizumab, we suggest that focal lung toxicity may be a
pattern of checkpoint inhibitor-associated lung injury. We also
summarize our experience with 4 additional patients who devel-
oped pulmonary inﬁltrates while being treated with PD-1
inhibitors.2. Case report
A 58-year-old woman diagnosed with stage IV lung adenocar-
cinoma 8 months earlier presented with a 2-week history of pro-
gressive exertional dyspnea and non-productive cough. She had
been treated initially with ﬁrst-line systemic chemotherapy using
carboplatin, pemetrexed, and pembrolizumab (2 mg/kg). Four cy-
cles of induction chemotherapy resulted in an excellent partial
response (Response Evaluation Criteria in Solid Tumors [RECIST] v
1.1[9]). As part of a clinical trial, maintenance pembrolizumab (2
mg/kg) every 3 weeks was then started, 5 months prior to her
current presentation. Currently, she denied fever, chills, chest pain,
hemoptysis, palpitations, pedal edema, orthopnea, or pleuritic
chest pain. She was a 60-pack-year smoker.
On examination, she was afebrile and in mild respiratorynder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ambulation. Her chest examination showed a focal wheeze over the
right middle lobe. There was no cyanosis, clubbing, or edema.
Laboratory assessment included a normal total leukocyte count and
hemoglobin. A complete metabolic panel was normal. Two blood
cultures were negative.
Compared with images from 5 weeks earlier, a contrast-
enhanced chest CT showed new focal airspace opacities in the
right middle lobe (Fig. 1A). There was no evidence of pulmonary
embolism. In addition, there was evidence of persistent/residual
tumor in the form of a spiculated right upper lobe density. Bron-
choscopy showed no endobronchial lesions or airway secretions.
Bronchoalveolar lavage (BAL) ﬂuid was predominantly neutrophilic
(N 39, L5, M48, E3). Cultures of the BAL ﬂuid were negative, as were
special stains for microorganisms. A transbronchial biopsy of theFig. 1. Chest CT. A. right middle lobe consolidation (arrow) at the time of presentation.
B. The inﬁltrate has resolved 1 month later after treatment with prednisone and
cessation of pembrolizumab.right middle lobe was performed. It included mainly bronchial wall
fragments with minute portions of attached alveolated lung. A
moderate to severe inﬂammatory inﬁltrate was seen in the bron-
chial mucosa, with pathologic evidence of damage to the bronchial
epithelium. The inﬂammatory inﬁltrate in the bronchial mucosa
was composed mainly of lymphocytes and eosinophils (Fig. 2A).
Only a few of these inﬂammatory cells extended into adjacent
alveolar septa. As expected in a reactive inﬂammatory inﬁltrate, the
lymphocytes were mainly CD3-positive T cells (CD4>CD8)
(Fig. 2BeE).
No antibiotics were prescribed. Based on clinical suspicion for
drug-associated lung toxicity and compatible pathologic ﬁndings,
pembrolizumab was stopped and she was treated with prednisone
(1 mg/kg/day) with a taper to discontinuation over 8 weeks. Over
the ﬁrst 3 days on prednisone, her symptoms improved markedly.
At her 1-month outpatient follow-up visit, her symptoms had
resolved completely. A follow-up chest CT showed complete reso-
lution of the right middle lobe inﬁltrate (Fig. 1B).
The main role of lung biopsy in the diagnosis of drug-associated
lung toxicity is the exclusion of alternative diagnoses such as
infection or tumor. In addition, although histologic ﬁndings are
never pathognomonic of drug toxicity, the identiﬁcation of an in-
ﬂammatory inﬁltrate in the lung in the absence of an obvious eti-
ology can be helpful in supporting the clinical impression of drug
toxicity. In the current case, there was no evidence of a speciﬁc
alternative pathologic diagnosis, and the composition of the in-
ﬂammatory inﬁltrate (lymphocytes and eosinophils) was compat-
ible with drug-associated toxicity. This impression was supported
by the lack of objective evidence of infection and prompt resolution
of clinical and radiographic ﬁndings with corticosteroid therapy.
Based on these ﬁndings, we suspected pembrolizumab-induced
focal lung toxicity and pembrolizumab was discontinued. The pa-
tient is currently being monitored off cancer-directed therapy
without evidence of disease progression at the time of this writing.
To extend available reports in the literature on PD-1 inhibitor-
associated pneumonitis, we also reviewed clinical records in 4
additional patients seen at Cleveland Clinic in the 7 months be-
tween September 2015 and March 2016 (Table 1), of whom one
showed a predominantly unilobar inﬁltrate (Case 1).
3. Discussion
Our patient's presentation and clinical course suggested pem-
brolizumab as the cause of a right middle lobe inﬁltrate. Although
checkpoint inhibitors have been implicated as a cause of diffuse
and/or multifocal pulmonary inﬁltrates, focal disease has not been
reported, making the current case novel. It is possible that the
blockade of immune tolerance that is the hallmark of PD-1 in-
hibitors might cause atypical inﬂammatory reactions such as focal
lobar inﬁltrates.
This report extends the available experience of adverse pul-
monary reactions with PD-1 inhibitors, which have been reported
in 1e11% of phase 2 and 3 trial participants [6]. In ameta-analysis of
PD-1 inhibitor-related pulmonary reactions, Abdel-Rahman et al.
reported severe (National Cancer Institute [NCI] Common Termi-
nology Criteria for Adverse Events [CTCAE] [8] grade 3/4) toxicity in
0.3e2% of patients treated with these drugs and “low grade” (NCI
CTCAE grade 1/2 8) toxicity in 1e9% [6]. Respiratory failure and
death from pneumonitis have also been anecdotally described
[5,7,10].
To our knowledge, the current report is the ﬁrst to describe
possible PD-1 inhibitor-associated focal pulmonary toxicity, and is
also the ﬁrst to report details of the pathologic ﬁndings associated
with this novel manifestation of checkpoint inhibitor-associated
pulmonary toxicity. The possibility of drug-associated toxicity
Fig. 2. Transbronchial biopsy ﬁndings. A. An inﬂammatory inﬁltrate composed of lymphocytes and eosinophils is seen within the bronchial mucosa (arrow and inset, bottom left).
There is evidence of damage to the bronchial epithelium in the form of denudation of surface ciliated columnar cells and reactive changes in the basal epithelium (arrowhead). B-E.
The lymphocytes are mainly T-cells, CD4>CD8 (B. CD3. C. CD20. D. CD4. E. CD8).
Table 1
Summary of patients with checkpoint inhibitor-ascribed pulmonary toxicity (Cleveland clinic, September 2015eMarch 2016).
Age(y)/Gender Diagnosis Stage Drug Dose
(mg/kg)
Chest CT ﬁndings Treatment Follow-up
1 50/F NSCLC IV Nivolumab 3 Patchy GGO, right upper lobe Prednisone 3 month- resolution of symptoms
and GGO
2 65/F RCC IV Nivolumab 3 Septal thickening with bibasilar
GGO
Prednisone NA
3 58/F NSCLC IV Nivolumab 3 GGO, bronchial thickening Prednisone NA
4 57/M SmCC IV Pembrolizumab 2 Centrilobular nodules, RML/RLL Prednisone 1 month- resolution of symptoms,
stable nodules
5a 58/F NSCLC IV Pembrolizumab 2 Consolidation, RML Prednisone 1 month- resolution of symptoms
and consolidation
Legend: NSCLC: Non-small cell lung carcinoma, SmCC: Small cell carcinoma, RCC: Renal cell carcinoma, GGO: Ground glass opacities, RML: Right middle lobe, RLL: Right lower
lobe, NA- Not available.
a Present case.
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are encountered in individuals being treated with PD-1 inhibitors.References
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